Myriad Genetics Inc (MYGN)
Return on equity (ROE)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | -127,300 | -263,300 | -112,000 | -27,200 | -223,700 |
Total stockholders’ equity | US$ in thousands | 701,100 | 783,200 | 885,800 | 967,800 | 881,000 |
ROE | -18.16% | -33.62% | -12.64% | -2.81% | -25.39% |
December 31, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-127,300K ÷ $701,100K
= -18.16%
Myriad Genetics Inc's return on equity (ROE) has experienced fluctuations over the years as per the provided data. In December 31, 2020, the ROE was at a significant low of -25.39%, indicating that the company was generating a negative return on shareholders' equity.
By December 31, 2021, there was a slight improvement in ROE, with the percentage improving to -2.81%. However, it still remained negative, albeit to a lesser extent.
In December 31, 2022, the ROE further decreased to -12.64%, indicating a decline in the company's ability to generate profit from its shareholders' equity. This negative trend continued into December 31, 2023, with an ROE of -33.62%, signifying a substantial deterioration in profitability relative to equity.
By December 31, 2024, there was a slight recovery in the ROE to -18.16%, but it remained negative. Overall, Myriad Genetics Inc's ROE trend suggests ongoing challenges in generating satisfactory returns on shareholders' equity, indicating a need for the company to address underlying issues affecting profitability and efficiency.
Peer comparison
Dec 31, 2024